"Designing Growth Strategies is in our DNA"

Lung Cancer Therapeutics Market Size, Share and Industry Analysis By Therapy (Targeted, Therapy, Immunotherapy, Chemotherapy), By Cancer Type (Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecast 2019-2026

Region : Global | Format: PDF | Report ID: FBI100473

 

Table of Content:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4. Key Insights

4.1 Prevalence of Lung Cancer by Key Countries

4.2 Regulatory Scenario by Key Regions

4.3 Key Industry Developments

4.4 Overview of Current Advances in R&D for Lung Cancer Therapeutics

4.5 Pipeline Analysis

5. Global Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Therapy

5.2.1 Targeted Therapy

5.2.1.1 Bevacizumab

5.2.1.2 Dabrafenib/Trametinib 

5.2.1.3 Erlotinib Hydrochloride

5.2.1.4 Osimertinib

5.2.1.5 Others

5.2.2 Immunotherapy

5.2.2.1 Durvalumab

5.2.2.2 Nivolumab 

5.2.2.3 Atezolizumab

5.2.2.4 Pembrolizumab

5.2.3 Chemotherapy

5.3. Market Analysis, Insights and Forecast – By Distribution Channel

5.3.1 Hospital Pharmacies

5.3.2 Retail Pharmacies

5.3.3 Online Pharmacies

5.3.4 Others

5.4 Market Analysis, Insights and Forecast – By Cancer Type

5.4.1 Non-small cell lung cancer (NSCLC)

5.4.2 Small cell lung cancer (SCLC)

5.5. Market Analysis, Insights and Forecast – By Region

5.5.1 North America

5.5.2 Europe

5.5.3 Asia Pacific

5.5.4 Latin America

5.5.5 Middle East & Africa

6. North America Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026

6.1. Key Findings / Summary

6.2. Market Analysis – By Therapy

6.2.1 Targeted Therapy

6.2.1.1 Bevacizumab

6.2.1.2 Dabrafenib/Trametinib 

6.2.1.3 Erlotinib Hydrochloride

6.2.1.4 Osimertinib

6.2.1.5 Others

6.2.2 Immunotherapy

6.2.2.1 Durvalumab

6.2.2.2 Nivolumab 

6.2.2.3 Atezolizumab

6.2.2.4 Pembrolizumab

6.2.3 Chemotherapy

6.3. Market Analysis – By Distribution Channel

6.3.1 Hospital Pharmacies

6.3.2 Retail Pharmacies

6.3.3 Online Pharmacies

6.3.4 Others

6.4. Market Analysis – By Cancer Type

6.4.1 Non-small cell lung cancer (NSCLC)

6.4.2 Small cell lung cancer (SCLC)

6.5. Market Analysis – By Country

6.5.1 U.S.

6.5.2 Canada

7. Europe Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026

7.1. Key Findings / Summary

7.2. Market Analysis – By Therapy

7.2.1 Targeted Therapy

7.2.1.1 Bevacizumab

7.2.1.2 Dabrafenib/Trametinib 

7.2.1.3 Erlotinib Hydrochloride

7.2.1.4 Osimertinib

7.2.1.5 Others

7.2.2 Immunotherapy

7.2.2.1 Durvalumab

7.2.2.2 Nivolumab 

7.2.2.3 Atezolizumab

7.2.2.4 Pembrolizumab

7.2.3 Chemotherapy

7.3. Market Analysis – By Distribution Channel

7.3.1 Hospital Pharmacies

7.3.2 Retail Pharmacies

7.3.3 Online Pharmacies

7.3.4 Others

7.4. Market Analysis – By Cancer Type

7.4.1 Non-small cell lung cancer (NSCLC)

7.4.2 Small cell lung cancer (SCLC)

7.5. Market Analysis – By Country/Sub-region

7.5.1 Germany

7.5.2 U.K.

7.5.3 France

7.5.4 Italy

7.5.5 Spain

7.5.6 Scandinavia

7.5.7 Rest of Europe

8. Asia Pacific Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026

8.1. Key Findings / Summary

8.2. Market Analysis – By Therapy

8.2.1 Targeted Therapy

8.2.1.1 Bevacizumab

8.2.1.2Dabrafenib/Trametinib 

8.2.1.3 Erlotinib Hydrochloride

8.2.1.4 Osimertinib

8.2.1.5 Others

8.2.2 Immunotherapy

8.2.2.1 Durvalumab

8.2.2.2 Nivolumab 

8.2.2.3 Atezolizumab

8.2.2.4 Pembrolizumab

8.2.3 Chemotherapy

8.3. Market Analysis – By Distribution Channel

8.3.1 Hospital Pharmacies

8.3.2 Retail Pharmacies

8.3.3 Online Pharmacies

8.3.4 Others

8.4. Market Analysis – By Cancer Type

8.4.1 Non-small cell lung cancer (NSCLC)

8.4.2 Small cell lung cancer (SCLC)

8.5. Market Analysis – By Country/ Sub-region

8.5.1 China

8.5.2 India

8.5.3 Japan

8.5.4 Australia

8.5.5 Southeast Asia

8.5.6 Rest of Asia Pacific

9. Latin America Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026

9.1. Key Findings / Summary

9.2. Market Analysis – By Therapy

9.2.1 Targeted Therapy

9.2.1.1 Bevacizumab

9.2.1.2 Dabrafenib/Trametinib 

9.2.1.3 Erlotinib Hydrochloride

9.2.1.4 Osimertinib

9.2.1.5 Others

9.2.2 Immunotherapy

9.2.2.1 Durvalumab

9.2.2.2 Nivolumab 

9.2.2.3 Atezolizumab

9.2.2.4 Pembrolizumab

9.2.3 Chemotherapy

9.3. Market Analysis – By Distribution Channel

9.3.1 Hospital Pharmacies

9.3.2 Retail Pharmacies

9.3.3 Online Pharmacies

9.3.4 Others

9.4. Market Analysis – By Cancer Type

9.4.1 Non-small cell lung cancer (NSCLC)

9.4.2 Smallcell lung cancer (SCLC)

9.5. Market Analysis – By Country/ Sub-Region

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Rest of Latin America

10. Middle East &Africa Lung Cancer Therapeutics Market Analysis, Insights and Forecast,2015-2026

10.1. Key Findings / Summary

10.2. Market Analysis – By Therapy

10.2.1 Targeted Therapy

10.2.1.1 Bevacizumab

10.2.1.2 Dabrafenib/Trametinib 

10.2.1.3 Erlotinib Hydrochloride

10.2.1.4 Osimertinib

10.2.1.5 Others

10.2.2 Immunotherapy

10.2.2.1 Durvalumab

10.2.2.2 Nivolumab 

10.2.2.3 Atezolizumab

10.2.2.4 Pembrolizumab

10.2.3 Chemotherapy

10.3. Market Analysis – By Distribution Channel

10.3.1 Hospital Pharmacies

10.3.2 Retail Pharmacies

10.3.3 Online Pharmacies

10.3.4 Others

10.4. Market Analysis – By Cancer Type

10.4.1 Non-smallcell lung cancer (NSCLC)

10.4.2 Smallcell lung cancer (SCLC)

10.5. Market Analysis – By Country/ Sub-region

10.5.1 South Africa

10.5.2 GCC Countries

10.5.3 Rest of Middle East & Africa

11. Competitive Analysis

11.1. Key Industry Developments

11.2. Global Market Share Analysis (2018)

11.3. Competition Dashboard

11.4. Comparative Analysis –Major Players

11.5. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability))

11.5.1 Genentech,Inc. (F. Hoffmann-La Roche Ltd)

11.5.2 EliLilly and Company

11.5.3 CelgeneCorporation

11.5.4 AstraZeneca

11.5.5 PfizerInc.

11.5.6 Sanofi

11.5.7 Novartis AG

11.5.8 Astellas Pharma Inc.

11.5.9 Bristol-Myers Squibb Company

11.5.10 Boehringer Ingelheim Pharmaceuticals, Inc.

11.5.11 Millennium Pharmaceuticals, Inc. (Takeda)

11.5.12 MerckSharp & Dohme Corp.

11.5.13 Other Prominent Players

 

12. Strategic Recommendations

 class=
  • Jun, 2019
  • 2018
  • 2015-2017
  • 159

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Healthcare Clients

DUPONT
Abbott
baxter
lpsos
Logo_Merck_KGaA_2015
chong-kun-dang
DAEWOONG
Natus-Medical
SUANFARMA
Bio-Rad
Intuitive_Surgical_logo
novo-nordisk
Ge-Healthcare
Sedana-Cyan-Black-Tag

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X